Immix Net Tangible Assets from 2010 to 2025

IMMX Stock  USD 1.94  0.03  1.52%   
Immix Biopharma Net Tangible Assets yearly trend continues to be fairly stable with very little volatility. Net Tangible Assets are likely to outpace its year average in 2025. Net Tangible Assets is the total assets of Immix Biopharma minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. View All Fundamentals
 
Net Tangible Assets  
First Reported
2010-12-31
Previous Quarter
15.1 M
Current Value
15.9 M
Quarterly Volatility
9.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immix Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immix Biopharma's main balance sheet or income statement drivers, such as Tax Provision of 12.5 K, Net Interest Income of 414.7 K or Depreciation And Amortization of 6.6 K, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 6.91 or Book Value Per Share of 0.88. Immix financial statements analysis is a perfect complement when working with Immix Biopharma Valuation or Volatility modules.
  
Check out the analysis of Immix Biopharma Correlation against competitors.
For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.

Latest Immix Biopharma's Net Tangible Assets Growth Pattern

Below is the plot of the Net Tangible Assets of Immix Biopharma over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Immix Biopharma's Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immix Biopharma's overall financial position and show how it may be relating to other accounts over time.
Net Tangible Assets10 Years Trend
Slightly volatile
   Net Tangible Assets   
       Timeline  

Immix Net Tangible Assets Regression Statistics

Arithmetic Mean2,133,734
Coefficient Of Variation425.09
Mean Deviation8,083,154
Median(3,646,358)
Standard Deviation9,070,220
Sample Variance82.3T
Range22.7M
R-Value0.79
Mean Square Error33.6T
R-Squared0.62
Significance0.0003
Slope1,499,046
Total Sum of Squares1234T

Immix Net Tangible Assets History

202515.9 M
202415.1 M
202213.2 M
202118 M
2020-4.7 M

About Immix Biopharma Financial Statements

Immix Biopharma investors use historical fundamental indicators, such as Immix Biopharma's Net Tangible Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immix Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Tangible Assets15.1 M15.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.